30 November 2020 : Clinical Research
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
Chang Liu12CDEF, Ting Li12CDEF, Zhonghua Tao12B, Jun Cao12B, Leiping Wang12B, Jian Zhang12B, Biyun Wang12A, Xichun Hu12A*DOI: 10.12659/MSM.927187
Med Sci Monit 2020; 26:e927187
Figure 1 Flowchart of the treatment pattern of palbociclib plus endocrine therapy and subsequent therapy. ET – endocrine therapy; HR+ – hormone receptor-positive; HER2 – human epidermal growth factor receptor 2; MBC – metastatic breast cancer; FUSCC – Fudan University Shanghai Cancer Center; SERD – selective estrogen receptor degrader; AI – aromatase inhibitor; SERM – selective estrogen receptor modulator